Genmab secures two additional approvals: Nordic Biotech and Healthcare (week 40)

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Genmab got two approvals in Japan and Europe, Biosergen entered into collaboration with an Indian company, and ExpreS2ion announced changes to their management team. Furthermore, the 3 best healthcare stocks in the Nordics in the past week all rose more than 40%.

In the past week, 5 of the 20 listed Danish biotech companies publishing news. Only 5 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year to date. Cessatech continues to be the best performing stock year-to-date with a 166% increase.

Company news the past week

Ascendis Pharma

No news the past week


Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections (Link)


No news the past week

CS Medica

No news the past week


No news the past week

Evaxion Biotech

No news the past week


Warrants of series TO 8 were exercised to approximately 18.5 percent and ExpreS2ion receives approximately SEK 3.4 million (Link)

ExpreS2ion announces changes to leadership team (Link)


No news the past week


EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) (Link)

Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) (Link)


No news the past week

Initiator Pharma

Result of incentive program LTI2023 in Initiator Pharma (Link)

IO Biotech

No news the past week

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


No news the past week

Zealand Pharma

Total number of shares and voting rights in Zealand Pharma at September 29, 2023 (Link)

Y-mAbs Therapeutics

No news the past week


No news the past week



On average, the Danish biotech stocks delivered a positive share price performance last week of 4.8%. Biosergen rose 77% without even announcing any news. ViroGates followed with a 24% increase after announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis. Notably, Evaxion only rose 4% after expanding preclinical bacterial pipeline with a leading pharmaceutical company as well as entered a partnership to develop a vaccine against gonorrhea. On the other hand, Ascendis Pharma fell the most with a 7% decrease following results of a trial with TransCon. The best stocks year-to-date include Curasight, Cessatech Fluoguide, and Saniona after soaring 87-154%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 3.3%. However, it is driven by the few companies delivering very positive returns.

Read more about Curasight (in Danish): Et succesfuldt kvartal for Curasight med mere i vente

Overview of share price developments the past week, year-to-date and last twelve months

Development in Nordic healthcare sector the past week

In the past week, Kapital Partner Nordic Healthcare Index (KPHC) fell 1,3%. Kapital Partner Nordic Healthcare Index tracks every healthcare company in the Nordics. It includes large cap companies such as Novo Nordisk and Genmab as well as smaller companies as Curasight.

The index development for Kapital Partner Healthcare Index the past year

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

The 3 best performing Nordic healthcare stocks the past week

ProstaLund AB (45%) (Nordnet) focus on the area of treatment of benign prostate enlargement (BPH). Through the company CoreTherm, heat treatment of benign prostate enlargement is offered, without the need for surgical operation. The vision is to offer both faster and more efficient solutions against traditional forms of infestation.

Lifecare AS (43%) (Nordnet) specializes in the research and development of diabetes. The products are patented and used as glucose sensors. The microsensors are injected under the skin of the patient’s wrist, and further function as a real-time update of the patient’s glucose level. In addition, the technology contributes with an alarm sensor and access to historical data on the patient’s glucose level.

Inhalation Sciences Sweden AB (42%) (Nordnet) focus is on the production and development of laboratory instruments. The instruments are used to measure particles in inhalation air, and to measure how the composition of the air affects the lungs. The company sells products under various trademarks, mainly on the European market. The share price rose following a collaboration deal with an Indian company.


Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.


Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email.